Innovative Pipeline Ocuphire Pharma, now operating under Opus Genetics, is focused on developing novel gene therapies for inherited retinal diseases and other ophthalmic disorders, presenting opportunities for advanced biotech and pharmaceutical service providers to support clinical development and regulatory processes.

Strategic Funding With a recent $23 million direct offering and non-dilutive funding from the Retinal Degeneration Fund, the company is actively investing in preclinical and clinical trials, indicating potential for partnerships in research, clinical trial management, and financing solutions.

Research & Events Regular participation in industry conferences and recent clinical trial launches suggest that the company values cutting-edge research and thought leadership, making it receptive to collaborations in medical communications, scientific advisory, and event sponsorship.

Technology Stack Utilizing advanced web and analytics tools such as Google Analytics, Cloudflare, and WP Engine, the company demonstrates a focus on digital presence and data-driven decision-making, opening avenues for digital marketing, IT solutions, and cybersecurity services.

Market Position Operating with a small team and a revenue range under $10 million, Ocuphire Pharma presents growth opportunities for scalable vendor solutions, including contract manufacturing, laboratory services, and specialist consulting to support expansion and operational efficiency.